Abacavir/lamivudine

Abacavir/lamivudine
Combination of
Abacavir	Nucleotide analogue reverse transcriptase inhibitor
Lamivudine	Nucleotide analogue reverse transcriptase inhibitor
Clinical data
Trade names	Kivexa, Epzicom, others
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a696011
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	J05AR02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	136470-78-5 136470-78-5 ; 134678-17-4 ;
PubChem CID	5273759;
UNII	WR2TIP26VS; 2T8Q726O95 ;
KEGG	D08775;
NIAID ChemDB	225604;
CompTox Dashboard (EPA)	DTXSID90234433 ;
	(what is this?) (verify)

Abacavir/lamivudine, sold under the brand name Kivexa among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS.^[3] It contains abacavir and lamivudine.^[3] It is generally recommended for use with other antiretrovirals.^[3] It is commonly used as part of the preferred treatment in children.^[4] It is taken by mouth as a tablet.^[3]

Trade namesKivexa, Epzicom, others

Quick facts Combination of, Lamivudine ...

Close

Common side effects include trouble sleeping, headache, depression, feeling tired, nausea, rash, and fever.^[3] Serious side effects may include high blood lactate levels, allergic reactions, and enlargement of the liver.^[3] It is not recommended in people with a specific gene known as HLA-B*5701.^[3] Safety in pregnancy has not been well studied but it appears to be okay.^[5] Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI).^[3]

Abacavir/lamivudine was approved for medical use in the United States in 2004.^[3] It is on the World Health Organization's List of Essential Medicines.^[6]

Society and culture